RadiusXR publishes NOVA clinical trial results for virtual reality perimetry

(Image Credit: AdobeStock/sdecoret)

RadiusXR announced the publication of its NOVA clinical trial in Translational Vision Science and Technology (TVST), a journal by the Association for Research in Vision and Ophthalmology (ARVO).

According to the company’s news release,¹ the NOVA clinical trial has found statistical non-inferiority to current clinical standards for sensitivities at individual test locations, glaucoma staging using Medicare definitions and an exceptionally high correlation of 0.94 in mean deviation.²

The company noted these results underscore the accuracy and reliability of RadiusXR's approach to visual field testing for head-mounted virtual reality perimetry.

Moreover, unlike other virtual reality perimeters (VRPs), RadiusXR measures vision within the photopic range, aligning with existing visual field platforms' standards. This alignment enables consistent clinical training and facilitates comparison to patients' prior examinations, as normative databases and mean deviation/pattern standard deviation (MD/PSD) plots are based on the photopic range.²

Ammad Khan, RadiusXR's CEO, said the publication of the results from NOVA was a milestone for the company.

“Our proprietary technology, combined with spatial computing, delivers unparalleled accuracy and precision, revolutionizing the diagnosis and management of ocular conditions,” he said in the news release.

Thomas Samuelson, MD, an ophthalmologist at Minnesota Eye Consultants in Minneapolis, lauded the findings of the clinical trial.

“The findings from the NOVA Clinical Trial are truly groundbreaking. RadiusXR's innovative approach to visual field testing represents a significant advancement in the field of ophthalmology,” he said in the news release. “This technology can potentially revolutionize how we diagnose and manage ocular conditions, ultimately improving patient outcomes and quality of life."

In July 2023, RadiusXR announced it entered into a collaboration and marketing agreement with Glaukos Corporation, a leading ophthalmic pharmaceutical and medical technology company, whereby Glaukos became the exclusive sales agent to market, promote, and solicit orders for RadiusXR in the United States. Radius continues to lead development and commercialization efforts for RadiusXR.

References

1. Translational Vision Science and Technology Journal Publishes RadiusXR’s NOVA Clinical Trial, Demonstrating Industry-Leading Accuracy and Innovation in Visual Field Testing for Virtual Reality Perimetry. www.businesswire.com. Published March 25, 2024. Accessed March 26, 2024. https://www.businesswire.com/news/home/20240325305764/en/Translational-Vision-Science-and-Technology-Journal-Publishes-RadiusXRs-NOVA-Clinical-Trial-Demonstrating-Industry-Leading-Accuracy-and-Innovation-in-Visual-Field-Testing-for-Virtual-Reality-Perimetry

2. Chris Bradley, Iqbal Ike K. Ahmed, Thomas W. Samuelson, Michael Chaglasian, Howard Barnebey, Nathan Radcliffe, Jason Bacharach; Validation of a Wearable Virtual Reality Perimeter for Glaucoma Staging, The NOVA Trial: Novel Virtual Reality Field Assessment. Trans. Vis. Sci. Tech. 2024;13(3):10. https://doi.org/10.1167/tvst.13.3.10.